Yes, agreed. (Not that I have an expert knowledge of immunology!) It seems to me that there is a cascade of subtle and interconnected immune abnormalities at work in ME.
I did see Klimas' presentation, but the quality of the image was poor in the video, so I couldn't make much sense of it. But it seems like an interesting theory that Klimas is working on, via a very sopphitcated computational model created by Gordon Broderick. If I understood it correctly, I think Klimas is working towards trialing a drug that will block IL-1.
These are my notes from
another thread:
Drug Trials:
Klimas wants to trial FDA approved drug (biological response modifier) that blocks IL-1 (cytokine). Computational data points towards blocking IL-1. Not able to get it past review board, because drug is toxic, and review boards don't appreciate the severity of ME. Lost 5 years due to not getting grant proposals past review boards. Requires phase I funding from private donors. Will, instead, look at other less optimal drugs (used for rheumatoid arthritis?) which she expects to get through review boards, but frustrated that she can't test the drug she wants to.